Ex-FDA commish Scott Gottlieb makes a quick jump back onto the money side of biotech
Well, that didn’t take long.
Just a little more than a month after Scott Gottlieb’s surprise exit at the FDA, the former commish is back on the money side of the industry he had been in charge of regulating for 2 years. He’s rejoining New Enterprise Associates as a full-time investing partner, where he expects to start backing biotech startups and sitting on boards again.
Axios got the scoop on Wednesday, which Gottlieb — who’s been well known for keeping his editorial contacts close — quickly confirmed in a Tweet.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,700+ biopharma pros reading Endpoints daily — and it's free.